Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Flonase Switch Approved, Branded Nasal Allergy Spray Market Will Grow In 2015

This article was originally published in The Tan Sheet

Executive Summary

Glaxo says Flonase Allergy Relief (fluticasone propionate 50 mcg spray) is the “first OTC nasal spray indicated for relief of all nasal and eye-related allergy symptoms.” The firm has not learned from FDA whether Flonase Allergy Relief will launch with market exclusivity.

You may also be interested in...



Perrigo Debuts On US National Brand Stage With OTC Switch Approval For Nasonex 24HR Allergy

Nasonex 24HR Allergy also will be first OTC mometasone furoate product available in US. It will compete in OTC intranasal corticosteroids category already led by other brands switched from Rx to nonprescription over past eight years.

RB Starts ‘Supercharge’ Diet To Be ‘Leaner, More Agile’ In Consumer Health

RB expects its “supercharge” cost-cutting strategy to yield as much as $228.5 million in annualized cost savings. The Mucinex marketer also says by 2020 it should compete almost exclusively in the consumer health, personal and household care markets.

RB Starts ‘Supercharge’ Diet To Be ‘Leaner, More Agile’ In Consumer Health

RB expects its “supercharge” cost-cutting strategy to yield as much as $228.5 million in annualized cost savings. The Mucinex marketer also says by 2020 it should compete almost exclusively in the consumer health, personal and household care markets.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS107059

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel